Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) today announced that it has retained KCSA Strategic Communications (” KCSA “), a leading New York City -based communications firm.

KCSA will work with management to create a comprehensive, strategic communications program to lead the Company’s public and investor relations programs. Since KCSA’s inception, nearly fifty years ago, the firm has developed a strong reputation for its work representing public companies with an expertise in several verticals including the psychedelics and cannabis industries. The engagement is designed to increase the awareness and help enhance the profile of Aion Therapeutic in the marketplace.

“As we enter the next phase of growth for the Company, we have retained KCSA to help broaden our exposure to the investment community and to represent us in the media,” commented Graham Simmonds , Executive Vice Chair and CEO of Aion Therapeutic. “Our Company is at a very exciting stage and we look forward to communicating how our patented approach of utilizing psilocybin and other mushroom compounds in combination with cannabinoids to treat serious medical conditions to the global medical community.”

Phil Carlson , Managing Director of KCSA Strategic Communications, commented, “At KCSA, our professionals have an extensive history of providing expert communications and strategy for our clients. With many decades of experience, we have built a vast network in both the media and investment communities that we will proactively begin to introduce to Aion Therapeutic’s management team. We are pleased to implement this communications plan based on best practices for Aion Therapeutic.”

For its services supporting the Company’s public relations and investor relations efforts, KCSA will receive Usd. $15,000 per month. The term of the engagement will be initially six months and then ongoing on a month-to-month basis. The Company has the right to terminate the relationship with KCSA on 90 days’ notice.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

About KCSA Strategic Communications

KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial services, technology and healthcare. Since 1969, the firm has demonstrated strategic thinking and program execution that drive results for clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com .

About Aion Therapeutic Inc.

Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.

DISCLAIMER & READER ADVISORY

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “may”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include regulatory and other third-party approvals; licensing and other risks. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE Aion Therapeutic Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2021/12/c3315.html

News Provided by Canada Newswire via QuoteMedia

Expects to file its 2020 Annual Financial Statements on or before May 31, 2021

Matica Enterprises Inc. (CSE: MMJ) (FSE: 39N) (OTC: MMJFF) (“Matica” or the “Company”) announces today that further to our news releases of May 3, 2021, the filing of the Company’s audited annual financial statements for the year ended December 31, 2020, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the “Annual Financial Statements”) remain outstanding. As part of the Company’s biweekly status report, Matica expects that the Annual Financial Statements together with the auditor’s report thereon should be finalized within fourteen days and filed, together with Matica’s annual management’s discussion and analysis for the 2020 fiscal year, by the next business day.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), an industry leader in full spectrum cannabidiol (CBD) hemp extract wellness products and probiotics, today reported financial results for the first quarter ended March 31, 2021. All dollars are stated in US Dollars.

Q1-2021 Financial Highlights

Keep reading... Show less

Premier cannabis brand consolidator and producer of cannabis-infused products INDVR Brands (CSE:IDVR) already has an impressive portfolio of brands with Cheech’s Stash and the award-winning Honu Brand as part of its roster. 

In the interview above, INDVR Brands CEO Joshua Mann shares the company’s efforts to support its expansion plans in the US and Canadian markets through the recent acquisition of all the assets of Nevada-based Strainz and Colorado-based Bronnor.

“The Strainz acquisition means merging of two extremely well aligned companies, and it brings in the Bronnor facility that is a 25,000 square foot state-of-the-art GMP-level manufacturing facility that also aligns it with another set with 700 dispensaries of distribution in Colorado,” Mann said. 

The cannabis market is rapidly changing and as demand grows, INDVR Brands already has the capacity to eventually manufacture and distribute products for areas and populations much larger than they’re currently made for. 

“We’re seeing the scheduling of cannabis at the US federal level. And at that point, there will be a path forward whereby a facility such as the Bronnor facility will give us an ability to distribute and produce for the entire western half of the United States,” Mann continued. 

“And that’s, I think, what it was originally built for. That’s what we saw as rationale with respect to where the merger was going, how do we future-proof ourselves?”

Watch the full interview with INDVR Brands (CSE:IDVR,OTC:AOF) CEO Joshua Mann above.

Keep reading... Show less

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MFNC, SPRT, WIFI, HRVSF; Shareholders are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies

Keep reading... Show less

Love Hemp Group PLC (“Love Hemp” or the “Company”) (Formerly World High Life Plc) Exercise of Warrants and Issue of Equity

Love Hemp Group PLC (AQSE:LIFE) (OTCQB:WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that it has received notifications from warrant holders to exercise warrants over 34,814,285 new ordinary shares of 1 pence each in the share capital of the Company (the ‘New Ordinary Shares’) at a price of 1 pence per share. Accordingly, the Company has today issued the New Ordinary Shares to the warrant holders for aggregate cash proceeds of £348,142. The proceeds will be used for general working capital purposes

Keep reading... Show less